Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 plus enlonstobart in recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2500112871Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CPO301 and PBI-1308 in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Objective Response Rate and Incidence of Adverse Events and Serious Adverse Events. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CPO301PBI-1308
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500112871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112871.